SCHEMBL5500320

SCHEMBL5500320

CC1CCC(C)C1.O=C(O)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
TSHR P16473 4/20 0.41
EPHX1 P07099 1/20 0.41
RECQL P46063 1/20 0.41
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
GABRA4 P48169 1/20 0.39
GABRE P78334 1/20 0.39
PMP22 Q01453 1/20 0.39
GABRA6 Q16445 1/20 0.39
GABRG1 Q8N1C3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL223962 0.88 EPHX1 (0.47) CES2CES1TSHREPHX1RECQL
SCHEMBL4265799 0.87 RECQL (0.42) CES2CES1TSHRRECQLGABRP
SCHEMBL15343955 0.86 CES2 (0.44) CES2CES1TSHREPHX1RECQL
SCHEMBL31733905 0.86 CES2 (0.48) CES2CES1TSHREPHX1RECQL
SCHEMBL16062725 0.86 CES2 (0.48) CES2CES1TSHREPHX1RECQL
SCHEMBL29221503 0.84 EPHX1 (0.42) CES2CES1TSHREPHX1RECQL
SCHEMBL13457435 0.83 TSHR (0.44) CES2CES1TSHREPHX1RECQL
Cyclohexane SCHEMBL28236664 0.83 CES2 (0.55) CES2CES1TSHRRECQLGABRP
SCHEMBL25212375 0.83 CES2 (0.61) CES2CES1TSHREPHX1RECQL
SCHEMBL242069 0.83 CES2 (0.61) CES2CES1TSHREPHX1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496911-B1 USE OF A COMBINATION COMPRISING A2A ADENOSINE RECEPTOR AGONISTS AND ANTI-PATHOGENIC AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES UNIV VIRGINIA (US) 2007-12-19 EP claimed